Mitochondrial fission - a drug target for cytoprotection or cytodestruction?
Ayeshah A Rosdah, Jessica K Holien, Lea MD Delbridge, Gregory J Dusting, Shiang Y Lim
PHARMACOLOGY RESEARCH & PERSPECTIVES | JOHN WILEY & SONS LTD | Published : 2016
Mitochondria are morphologically dynamic organelles constantly undergoing processes of fission and fusion that maintain integrity and bioenergetics of the organelle: these processes are vital for cell survival. Disruption in the balance of mitochondrial fusion and fission is thought to play a role in several pathological conditions including ischemic heart disease. Proteins involved in regulating the processes of mitochondrial fusion and fission are therefore potential targets for pharmacological therapies. Mdivi-1 is a small molecule inhibitor of the mitochondrial fission protein Drp1. Inhibiting mitochondrial fission with Mdivi-1 has proven cytoprotective benefits in several cell types inv..View full abstract
This work was supported by grants from the National Health and Medical Research Council of Australia, St Vincent's Hospital (Melbourne) Research Endowment Fund and Stafford Fox Medical Research Foundation.